renac
What it found
No result yet.
What was tested
Treatment tested
- Acetylcysteine
Glutathione precursor|Mycolytic
What it measured
Main measures
safety and efficacy
Safety
Who could take part
Relapsing MS
Inclusion: 1. Subjects must be between the ages of 18 and 50 years inclusive. Exclusion: 1. Use of experimental or investigational drugs, including I.V. immunoglobulin, within 6 months prior to study entry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
 To evaluate the effect of combination therapy IFN beta 1a 44 mcg t.i.w. + 1200 mg N-Acetyl Cysteine vs IFN beta 1a 44 mcg t.i.w. + placebo on neurodegeneration as assessed by MRI spectroscopy during 24 months of treatment in subject with RR MS
Loading reviews and guidelines…
Related trials
- The Effect of Metformin As an Adjuvant Therapy on Immunol…
Phase 2 · Completed
Missed its main goal
- CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-…
Phase 2 · Completed
Result in a paper, not read yet
- VISIONMS-LTE
Phase 2 / Phase 3 · Completed
No result found
- MS
Not a drug-phase study · Completed
Result in a paper, not read yet
- VISIONARY-MS
Phase 2 · Stopped early
Stopped early
History
Started
Mar 2008
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error